Joint Study by Rosetta Genomics and NYU Langone Medical Center Identifies Potential microRNA Drug Target for Mesothelioma

by Chris on May 24, 2010

in News

REHOVOT, Israel & PHILADELPHIA–(BUSINESS WIRE)–Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announced today that the results of a joint study with the NYU Langone Medical Center were published on May 12th, 2010 in the online issue of The Journal of Biological Chemistry. The study “Pro-tumorigenic Effects of miR-31 Loss in Mesothelioma,” demonstrates the potential of miR-31 to be used for the development of new therapies against mesothelioma and other cancers. The study may be viewed online at:

In the study, cell lines derived from mesothelioma patients were found not to express miR-31, a microRNA that has recently been characterized as a suppressor of breast cancer metastases. Functional assessment of miR-31 activity revealed its ability to inhibit proliferation, migration, invasion, and clonogenicity of mesothelioma cells. Reintroduction of miR-31 suppressed cell cycle and inhibited expression of multiple factors involved in cooperative maintenance of DNA replication and cell cycle progression. (read more…)

Leave a Comment

Previous post:

Next post: